Novo Seeds’ portfolio company, IO Biotech, completes oversubscribed EUR 127m Series B financing to accelerate clinical programs in oncology

Novo Seeds, the early-stage investment and company creation team of Novo Holdings, announced today that its portfolio company, IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, has raised EUR 127 million in Series B financing.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...